Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 55.89 -0.57% -0.32
AGIO closed down 0.57 percent on Friday, January 18, 2019, on 1.4 times normal volume. It ran into resistance at its 50 day moving average. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical AGIO trend table...

Date Alert Name Type % Chg
Jan 18 50 DMA Resistance Bearish 0.00%
Jan 18 Weak + Overbought Other 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 50 DMA Resistance Bearish -0.57%
Jan 17 Weak + Overbought Other -0.57%
Jan 17 Wide Bands Range Expansion -0.57%
Jan 17 Overbought Stochastic Strength -0.57%
Jan 17 Up 3 Days in a Row Strength -0.57%
Jan 16 50 DMA Resistance Bearish -0.55%

Older signals for AGIO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Is AGIO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 99.82
52 Week Low 41.63
Average Volume 595,718
200-Day Moving Average 74.9988
50-Day Moving Average 56.8382
20-Day Moving Average 49.97
10-Day Moving Average 54.671
Average True Range 3.1927
ADX 26.55
+DI 21.7512
-DI 13.1659
Chandelier Exit (Long, 3 ATRs ) 48.0519
Chandelier Exit (Short, 3 ATRs ) 51.2081
Upper Bollinger Band 59.8131
Lower Bollinger Band 40.1269
Percent B (%b) 0.8
BandWidth 39.396038
MACD Line 0.4593
MACD Signal Line -0.8714
MACD Histogram 1.3307
Fundamentals Value
Market Cap 2.71 Billion
Num Shares 48.4 Million
EPS -6.33
Price-to-Earnings (P/E) Ratio -8.83
Price-to-Sales 59.19
Price-to-Book 6.21
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.48
Resistance 3 (R3) 59.52 58.38 58.88
Resistance 2 (R2) 58.38 57.46 58.35 58.68
Resistance 1 (R1) 57.13 56.90 56.56 57.09 58.48
Pivot Point 55.99 55.99 55.70 55.96 55.99
Support 1 (S1) 54.74 55.07 54.17 54.70 53.30
Support 2 (S2) 53.60 54.51 53.57 53.10
Support 3 (S3) 52.35 53.60 52.90
Support 4 (S4) 52.31